Cullinan Therapeutics, Inc. announced the appointment of Mary Kay Fenton as Chief Financial Officer, beginning April 29, 2024. Ms. Fenton has three decades of financial and operational experience in the biotechnology industry, including companies spanning diverse disease areas including immunology. Most recently, Ms. Fenton served as Interim Chief Executive Officer and Chief Financial Officer of Talaris Therapeutics, Inc.  She was Chief Financial Officer and Chief Operating Officer at Semma Therapeutics, which was acquired by Vertex, where Ms. Fenton served as Vice President, Strategic Operations for the Cell and Genetic Therapies unit.

Before Semma, Ms. Fenton was Chief Financial Officer of Achillion Pharmaceuticals, before its ultimate acquisition by AstraZeneca. In her various roles, Ms. Fenton was instrumental in company development and growth, leading both financial and operational functions and managing critical transactions including multiple public and private capital raises, strategic collaborations, and mergers and acquisitions.